ONESOURCE Onesource Specialty Pharma Q1 FY26 results (Apr–Jun 2025) and concall
OneSource Specialty Pharma delivered a strong Q1 FY26, characterized by significant margin expansion and a transition toward commercial-stage revenues. Management identified FY26 as a major inflection point, particularly as the company prepares for the global launch of Semaglutide generics starting in Q4. The strategic focus is currently on accelerating capacity and integrating two high-margin CDMO assets in Poland and Baroda.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|
| Revenue | 393 | 426 | 327 |
| EBITDA | 142 | 183 | 88 |
| Net profit | -69 | 98 | 0 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
